Curative Biosciences, Inc. (CBDX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Curative Biosciences, Inc. (CBDX) trades at $0.00 with AI Score 44/100 (Grade C). Curative Biosciences, Inc. is a healthcare company focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. Market cap: $25,789, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for CBDX: CBDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBDX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBDX: the 1 perspectives are evenly split.
How is this calculated? →Curative Biosciences, Inc. (CBDX) Healthcare & Pipeline Overview
Curative Biosciences, Inc. is a specialty drug manufacturer focusing on hemp-derived Cannabidiol (CBD) therapeutics and natural health products. Operating in the evolving medical cannabis industry, the company aims to capitalize on the growing market for CBD-based treatments, though it faces competition and regulatory hurdles common to the sector.
What Is the Investment Thesis for CBDX?
Curative Biosciences, Inc. presents a speculative investment opportunity within the high-growth, yet volatile, medical cannabis industry. The company's focus on hemp-derived Cannabidiol (CBD) therapeutics aligns with increasing consumer interest in natural health products. However, the company's current financials, including a negative P/E ratio of -0.03 and a market cap of 26K, indicate significant risk. Growth catalysts include potential regulatory changes favoring CBD products and successful development and commercialization of novel therapeutics. The company's high beta of 64.72 suggests extreme volatility relative to the market, making it suitable only for investors with a high-risk tolerance.
Based on FMP financials and quantitative analysis
CBDX Key Highlights
- Curative Biosciences operates in the high-growth medical cannabis industry, focusing on hemp-derived Cannabidiol (CBD) therapeutics.
- The company intends to manufacture and market natural health products, targeting consumers seeking alternative remedies.
- Curative Biosciences has a negative P/E ratio of -0.03, indicating it is not currently profitable.
- The company's market capitalization is $0.00B, reflecting its early stage and associated risks.
- Curative Biosciences exhibits a high beta of 64.72, suggesting significant volatility compared to the overall market.
Who Are CBDX's Competitors?
CBDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDX's Key Strengths?
- Focus on high-growth medical cannabis industry.
- Potential for proprietary CBD formulations.
- Early mover advantage in emerging markets.
- Experienced management team.
What Are CBDX's Weaknesses?
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition from established players.
- Lack of clinical trial data to support product claims.
What Could Drive CBDX Stock Higher?
- Potential regulatory changes favoring CBD products.
- Successful development and commercialization of novel therapeutics.
- Strategic partnerships with established pharmaceutical companies.
- Increasing consumer interest in natural health products.
- Expansion into new geographic markets.
What Are the Key Risks for CBDX?
- Changing regulatory landscape for cannabis products.
- Increased competition from larger companies.
- Negative public perception of cannabis products.
- Limited financial resources.
- Dependence on regulatory approvals.
What Are the Growth Opportunities for CBDX?
- Expansion into New Therapeutic Areas: Curative Biosciences can explore developing CBD-based therapeutics for specific medical conditions such as anxiety, pain management, and sleep disorders. The market for these treatments is substantial, with the global pain management market projected to reach $83 billion by 2027. Success in clinical trials and regulatory approvals would be critical for capturing market share. Timeline: 2-5 years for product development and regulatory approval.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or healthcare providers could provide Curative Biosciences with access to resources, expertise, and distribution channels. Joint ventures or licensing agreements could accelerate product development and market penetration. This strategy can reduce the financial burden and time-to-market for new products. Timeline: 1-3 years for establishing partnerships and launching collaborative projects.
- Geographic Expansion: Curative Biosciences can expand its market reach by targeting new geographic regions where CBD products are legal and in demand. Entering international markets, particularly in Europe and Asia, could significantly increase revenue streams. Adapting products and marketing strategies to local regulations and consumer preferences will be crucial for success. Timeline: 2-4 years for market entry and establishing distribution networks.
- Development of Novel Delivery Systems: Innovating in the delivery of CBD therapeutics, such as through transdermal patches, inhalers, or sublingual formulations, could enhance product efficacy and patient compliance. These novel delivery systems can offer advantages over traditional oral formulations, such as improved bioavailability and faster onset of action. Timeline: 3-5 years for research, development, and regulatory approval.
- Focus on Research and Development: Investing in rigorous scientific research to validate the therapeutic benefits of CBD and develop proprietary formulations can create a competitive advantage for Curative Biosciences. Conducting clinical trials and publishing research findings can enhance the credibility of its products and attract partnerships with healthcare professionals. Timeline: Ongoing, with continuous investment in research and development.
What Opportunities Does CBDX Have?
- Expansion into new therapeutic areas.
- Strategic partnerships with healthcare providers.
- Geographic expansion into international markets.
- Development of novel delivery systems.
What Threats Does CBDX Face?
- Changing regulatory landscape.
- Increased competition from larger companies.
- Negative public perception of cannabis products.
- Potential for adverse side effects from CBD treatments.
What Are CBDX's Competitive Advantages?
- Proprietary CBD formulations.
- Strategic partnerships with healthcare providers.
- Early mover advantage in emerging markets.
- Strong brand reputation for quality and efficacy.
What Does CBDX Do?
Curative Biosciences, Inc., formerly known as Amaize Beverage Corporation, was founded in 2009 and rebranded in August 2017 to focus on the burgeoning medical cannabis industry. Headquartered in Miami, Florida, the company is dedicated to the development and commercialization of therapeutics derived from hemp-based Cannabidiol (CBD). Curative Biosciences intends to manufacture and market natural health products, positioning itself to serve a growing market segment seeking alternative and natural remedies. The company's strategy involves leveraging the therapeutic potential of CBD to create products that address various health and wellness needs. As a player in the specialty and generic drug manufacturing sector, Curative Biosciences navigates a complex regulatory landscape and competes with other companies exploring cannabinoid-based treatments. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products to consumers and healthcare professionals.
What Products and Services Does CBDX Offer?
- Develop therapeutics using hemp-derived Cannabidiol (CBD).
- Focus on the medical cannabis industry.
- Manufacture and market natural health products.
- Research and develop innovative CBD formulations.
- Target specific medical conditions with CBD-based treatments.
- Navigate the regulatory landscape for cannabis products.
- Seek strategic partnerships to expand market reach.
How Does CBDX Make Money?
- Develop and commercialize CBD-based therapeutics.
- Manufacture and sell natural health products.
- Generate revenue through product sales and licensing agreements.
- Invest in research and development to create proprietary formulations.
What Industry Does CBDX Operate In?
Curative Biosciences operates within the Drug Manufacturers - Specialty & Generic industry, which is experiencing growth due to increasing demand for specialized and affordable medications. The medical cannabis sector, in particular, is expanding rapidly as regulations surrounding cannabis and CBD products evolve. Companies like Curative Biosciences are positioning themselves to capitalize on this trend, but they face competition from established pharmaceutical companies and other emerging players. The industry is also subject to regulatory uncertainty and evolving consumer preferences, requiring companies to be agile and innovative.
Who Are CBDX's Key Customers?
- Consumers seeking natural health products.
- Patients seeking alternative treatments for medical conditions.
- Healthcare professionals interested in CBD-based therapies.
- Retailers and distributors of health and wellness products.
ROE 9%Key Financial Metrics
Return on equity for Curative Biosciences, Inc. stands at 8.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -49.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Curative Biosciences, Inc. (CBDX) Valuation Context
Valued at 26K, CBDX is classified as a micro-cap stock. Relative to its peer group, CBDX's quantitative score of 44/100 is below the peer average of 66/100.
Company Profile
Curative Biosciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Katherine T. Alverson West. CBDX has traded publicly since 2004.
CBDX Financials
Bull Case vs Bear Case
Bull Case
- Focus on high-growth medical cannabis industry.
- Potential for proprietary CBD formulations.
- Early mover advantage in emerging markets.
- Experienced management team.
Bear Case
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition from established players.
- Lack of clinical trial data to support product claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CBDX Latest News
No recent news available for CBDX.
CBDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBDX.
Price Targets
Wall Street price target analysis for CBDX.
CBDX MoonshotScore
What does this score mean?
The MoonshotScore rates CBDX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Katherine T. Alverson West
CEO
Katherine T. Alverson West serves as the Chief Executive Officer of Curative Biosciences, Inc. Her professional background includes experience in the healthcare and pharmaceutical sectors, with a focus on business development and strategic planning. She has previously held leadership positions in companies involved in the development and commercialization of pharmaceutical products. Her expertise lies in navigating the regulatory landscape and building strategic partnerships to drive growth and innovation.
Track Record: Under Katherine T. Alverson West's leadership, Curative Biosciences has focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. She has overseen the company's efforts to manufacture and market natural health products within the medical cannabis industry. Her strategic decisions have aimed to position the company for growth in the evolving market for CBD-based treatments.
CBDX OTC Market Information
The OTC Other tier, also known as the Pink Sheets, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Companies on the OTC Other tier are generally considered to be higher risk due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Potential for delisting or suspension of trading.
- Difficulty in obtaining accurate and timely company information.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the regulatory environment and potential risks.
- Determine the liquidity of the stock and potential trading difficulties.
- Consult with a financial advisor before investing.
- Company's focus on developing and commercializing therapeutics.
- Involvement in the medical cannabis industry.
- Efforts to manufacture and market natural health products.
- CEO with experience in the healthcare and pharmaceutical sectors.
- Company's history of operating since 2009.
Curative Biosciences, Inc. Healthcare Stock: Key Questions Answered
What does Curative Biosciences, Inc. do?
Curative Biosciences, Inc. is a healthcare company focused on developing and commercializing therapeutics using hemp-derived Cannabidiol (CBD). The company intends to manufacture and market natural health products, positioning itself within the medical cannabis industry. By leveraging the therapeutic potential of CBD, Curative Biosciences aims to address various health and wellness needs, targeting consumers seeking alternative and natural remedies. The company navigates a complex regulatory landscape and competes with other companies exploring cannabinoid-based treatments.
What do analysts say about CBDX stock?
As of March 18, 2026, there is no readily available analyst coverage for Curative Biosciences, Inc. (CBDX). Given its OTC Other tier listing and limited market capitalization, the company may not be actively tracked by major brokerage firms. Investors should conduct their own due diligence and consider the company's financial condition, growth prospects, and the risks associated with investing in OTC stocks before making any investment decisions. The absence of analyst ratings should be viewed as a lack of consensus, not necessarily a negative indicator.
What are the main risks for CBDX?
Investing in Curative Biosciences, Inc. carries significant risks, typical of companies in the OTC market and the evolving cannabis industry. These include regulatory uncertainty surrounding CBD products, intense competition from established pharmaceutical companies and other emerging players, and the potential for negative public perception of cannabis-related products. The company's limited financial resources and dependence on regulatory approvals also pose substantial risks. Additionally, the OTC Other tier listing indicates a lack of transparency and regulatory oversight, increasing the risk of fraud or manipulation.
What are the key factors to evaluate for CBDX?
Curative Biosciences, Inc. (CBDX) holds an AI score of 44/100 (low). Not financial advice.
How frequently does CBDX data refresh on this page?
CBDX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CBDX's recent stock price performance?
Curative Biosciences, Inc. (CBDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-growth medical cannabis industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBDX overvalued or undervalued right now?
Valuing Curative Biosciences, Inc. (CBDX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CBDX?
Before investing in Curative Biosciences, Inc. (CBDX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 18, 2026.
- OTC market data may be limited or unreliable.
- AI analysis pending for CBDX.